Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 09/26/17 → 06/30/22 |
Funding
- National Cancer Institute: $8,383.00
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >1 CM Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After...
- Cohen, Jules (PI)
- Baer, Lea (CoPI)
- Stopeck, Alison (CoPI)
Project: Research